The upcoming annual American Society of Nephrology (ASN) Kidney Week 2018 is expecting to host 13000 delegates from across the globe. Antaros Medical, in collaboration with Sahlgrenska University Hospital and AstraZeneca, will present new exciting data showing that magnetic resonance imaging (MRI) is a non-invasive drug development tool that has increased precision, sensitivity and repeatability for chronic kidney disease (CKD). MRI has great potential to non-invasively assess functional and morphologic, including fibrotic, changes in the kidney that may improve diagnosis, prognosis and treatment monitoring in patients with CKD. Longitudinal follow-up will assess whether these findings can identify patients at risk for rapid progression of CKD.
Figure 1. Anatomical MR images of typical healthy volunteer (left), CKD3 subject (center) and CKD4 subject (right)
October 26th, Exhibit Hall, San Diego Convention Center
Presenter: Adjunct Professor Paul Hockings, Antaros Medical
Authors: Paul Hockings, Kianoush Makvandi, Tim Unnerstall, Henrik Leonhardt, Anna Frödén Löwenmark, Lisa Jarl, Camilla Englund, Susan Francis, Gert Jensen, Fredrik Erlandsson, Anna Sundgren-Andersson, Johannes Hulthe, Seema Baid-Agrawal
Time: October 26, 2018 | 10:00 AM – 12:00 PM
Category: 602 Diabetic Kidney Disease: Clinical – 1
Abstract Number: FR-PO427
Title: High Repeatability and Sensitivity of MR Imaging Biomarkers of CKD
Presenter: Adjunct Professor Paul Hockings, Antaros Medical
Authors: Kianoush Makvandi, Gert Jensen, Paul Hockings, Tim Unnerstall, Henrik Leonhardt, Lisa Jarl, Anna Frödén Löwenmark, Camilla Englund, Susan Francis, Johannes Hulthe, Seema Baid-Agrawal
Time: October 26, 2018 | 10:00 AM
Category: 602 Diabetic Kidney Disease: Clinical – 1
Abstract Number: FR-PO428